Advanced glycation end products in skeletal muscle health and sarcopenia: A systematic review of observational studies

Granic, Antoneta; Hurst, Christopher; Dismore, Lorelle; Dodds, Richard; Witham, Miles; Robinson, Siân; Sayer, Avan A.

doi:10.1016/j.mad.2022.111744

Cited by 8 publications

(3 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association was robust to adjustment for a range of factors, including other aspects of diet and baseline grip strength, and evident in subgroup and sensitivity analyses. This novel finding suggests a direct effect of UPF on muscle function, potentially via effects on low-grade inflammation [ 88 ] and/or through increased exposure to constituents that are linked to food processing, such as advanced glycation end products [ 89 ]. As diet quality captures high and low consumption of different foods, it provides a more complete assessment of dietary exposure, potentially also contributing to greater consistency across the evidence for dietary patterns than for individual foods.…”

Section: Discussionmentioning

confidence: 99%

The role of nutrition in the prevention of sarcopenia

Robinson,

Granic,

Cruz-Jentoft

et al. 2023

The American Journal of Clinical Nutrition

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The role of nutrition in the prevention of sarcopenia

Robinson,

Granic,

Cruz-Jentoft

et al. 2023

The American Journal of Clinical Nutrition

Self Cite

View full text Add to dashboard Cite

“…Concentrations of AGEs either in the skin or the circulation are higher in individuals with lower muscle mass and strength [ 73 ], both for the general population [ 74 , 75 ] and for individuals with T2DM [ 76 ]. Some, but not all, of these analyses suggest a dose-response between higher AGEs and lower muscle mass or strength.…”

Section: The Relationship Between Hyperglycaemic States and Skeletal ...mentioning

confidence: 99%

Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia – A Narrative Review

et al. 2023

Self Cite

View full text Add to dashboard Cite

Sarcopenia, the age-related loss of muscle strength and mass or quality, is a common condition with major adverse consequences. Although the pathophysiology is incompletely understood, there are common mechanisms between sarcopenia and the phenomenon of accelerated ageing seen in diabetes mellitus. Drugs currently used to treat type 2 diabetes mellitus may have mechanisms of action that are relevant to the prevention and treatment of sarcopenia, for those with type 2 diabetes and those without diabetes. This review summarises shared pathophysiology between sarcopenia and diabetes mellitus, including the effects of advanced glycation end products, mitochondrial dysfunction, chronic inflammation and changes to the insulin signalling pathway. Cellular and animal models have generated intriguing, albeit mixed, evidence that supports possible beneficial effects on skeletal muscle function for some classes of drugs used to treat diabetes, including metformin and SGLT2 inhibitors. Most human observational and intervention evidence for the effects of these drugs has been derived from populations with type 2 diabetes mellitus, and there is a need for intervention studies for older people with, and at risk of, sarcopenia to further investigate the balance of benefit and risk in these target populations. Not all diabetes treatments will be safe to use in those without diabetes because of variable side effects across classes. However, some agents [including glucagon-like peptide (GLP)-1 receptor agonists and SGLT2 inhibitors] have already demonstrated benefits in populations without diabetes, and it is these agents, along with metformin, that hold out the most promise for further investigation in sarcopenia.Extended author information available on the last page of the article Key PointsType 2 diabetes mellitus and sarcopenia share multiple pathophysiological mechanisms.Preclinical, observational and interventional data suggest that some drugs used to treat diabetes may have beneficial effects on sarcopenia even in patients without diabetes. Clinical trials of these agents have not focussed on enrolling people with sarcopenia, and such trials are needed to evaluate whether diabetes drugs could improve or prevent sarcopenia in patients with or without diabetes.

show abstract

“…Alternative pathways include the hexosamine pathway and the glyoxalase pathway [69,70], leading to additional generation of ROS and advanced glycation end (AGE) products [71][72][73][74]. Circulating levels of AGEs are negatively associated with muscle mass, muscle strength and physical function in older adults and are therefore implicated in development of sarcopenia [75][76][77][78].…”

Section: Metabolic Dysregulationmentioning

confidence: 99%

Old muscle, new tricks: a clinician perspective on sarcopenia and where to next

Schütze,

Schopp,

Fairchild

et al. 2023

Current Opinion in Neurology

View full text Add to dashboard Cite

Purpose of review This review offers a contemporary clinical approach to the recognition, prevention and management of sarcopenia, and discusses recent clinically relevant advances in the aetiopathogenesis of muscle ageing that may lead to future therapeutic targets. Recent findings The key recent directions for sarcopenia are in the diagnosis, understanding molecular mechanisms and management. Regarding the recognition of the condition, it has become increasingly clear that different definitions hamper progress in understanding. Therefore, the Global Leadership in Sarcopenia has been established in 2022 to develop a universally accepted definition. Moreover, substantial work is occurring to understand the various roles and contribution of inflammation, oxidative stress, mitochondrial dysfunction and metabolic dysregulation on skeletal muscle function and ageing. Finally, the role of resistance-based exercise regimes has been continually emphasised. However, the role of protein supplementation and hormone replacement therapy (HRT) are still under debate, and current clinical trials are underway. Summary With the global ageing of our population, there is increasing emphasis on maintaining good health. Maintenance of skeletal muscle strength and function are key to preventing frailty, morbidity and death.

show abstract

Advanced glycation end products in skeletal muscle health and sarcopenia: A systematic review of observational studies

Cited by 8 publications

References 55 publications

The role of nutrition in the prevention of sarcopenia

The role of nutrition in the prevention of sarcopenia

Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia – A Narrative Review

Old muscle, new tricks: a clinician perspective on sarcopenia and where to next

Contact Info

Product

Resources

About